Sirio secures TGA GMP certification to support strategic growth in Australia
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
The facility has been designed with a dual focus on efficiency and sustainability
The payment is in accordance with the agreed contractual terms
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Subscribe To Our Newsletter & Stay Updated